Fintel reports that on February 3, 2025, Redburn Atlantic upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to Buy.
Analyst Price Forecast Suggests 14.60% Upside
As of January 28, 2025, the average one-year price target for DexCom is $99.51/share. The forecasts range from a low of $75.75 to a high of $131.25. The average price target represents an increase of 14.60% from its latest reported closing price of $86.83 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for DexCom is 4,731MM, an increase of 19.65%. The projected annual non-GAAP EPS is 1.98.
What is the Fund Sentiment?
There are 1,863 funds or institutions reporting positions in DexCom. This is an decrease of 111 owner(s) or 5.62% in the last quarter. Average portfolio weight of all funds dedicated to DXCM is 0.14%, an increase of 59.53%. Total shares owned by institutions decreased in the last three months by 2.53% to 429,559K shares. 
The put/call ratio of DXCM is 0.84, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital Research Global Investors holds 17,948K shares representing 4.60% ownership of the company. In its prior filing, the firm reported owning 11,946K shares , representing an increase of 33.44%. The firm decreased its portfolio allocation in DXCM by 15.85% over the last quarter.
Baillie Gifford holds 14,613K shares representing 3.74% ownership of the company. In its prior filing, the firm reported owning 15,018K shares , representing a decrease of 2.77%. The firm decreased its portfolio allocation in DXCM by 55.03% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,726K shares representing 3.26% ownership of the company. In its prior filing, the firm reported owning 12,575K shares , representing an increase of 1.19%. The firm decreased its portfolio allocation in DXCM by 43.80% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 10,498K shares representing 2.69% ownership of the company. In its prior filing, the firm reported owning 10,207K shares , representing an increase of 2.77%. The firm decreased its portfolio allocation in DXCM by 44.03% over the last quarter.
Sands Capital Management holds 10,319K shares representing 2.64% ownership of the company. In its prior filing, the firm reported owning 10,607K shares , representing a decrease of 2.78%. The firm decreased its portfolio allocation in DXCM by 40.58% over the last quarter.
Dexcom Background Information
(This description is provided by the company.)
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
